US Public Health Service Clinical Practice Guideline: Treating tobacco use and dependence

Respiratory Care, vol. 45, issue 10 (2000) pp. 1200-1262 Published by Daedalus Enterprises Inc.

  • 7


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.
Sign in to save reference


Treating Tobacco Use and Dependence, a Public Health Service-sponsored Clinical Practice Guideline, is a product of the Tobacco Use and Dependence Guideline Panel ('the panel'), consortium representatives, consultants, and staff. These 30 individuals were charged with the responsibility of identifying effective, experimentally validated tobacco dependence treatments and practices. The updated guideline was sponsored by a consortium of seven Federal Government and nonprofit organizations: the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute, National Institute on Drug Abuse, Robert Wood Johnson Foundation, and University of Wisconsin Medical School's Center for Tobacco Research and Intervention. This guideline is an updated version of the 1996 Smoking Cessation Clinical Practice Guideline No. 18 that was sponsored by the Agency for Health Care Policy and Research (now the AHRQ), United States Department of Health and Human Services. The original guideline reflected the extant scientific research literature published between 1975 and 1994. The updated guideline was written because new, effective clinical treatments for tobacco dependence have been identified since 1994. The accelerating pace of tobacco research that prompted the update is reflected in the fact that 3,000 articles on tobacco were identified as published between 1975 and 1994, contributing to the original guideline. Another 3,000 were published between 1995 and 1999 and contributed to the updated guideline. These 6,000 articles were screened and reviewed to identify a much smaller group of articles that served as the basis for guideline data analyses and panel opinion. This guideline contains strategies and recommendations designed to assist clinicians, tobacco dependence treatment specialists, and health care administrators, insurers, and purchasers in delivering and supporting effective treatments for tobacco use and dependence. The recommendations were made as a result of a systematic review and analysis of the extant scientific literature, using meta-analysis as the primary analytic technique. The strength of evidence that served as the basis for each recommendation is clearly indicated in the guideline. A draft of the guideline was peer-reviewed prior to publication, and the comments of 70 external reviewers were incorporated into the final document. The key recommendations of the updated guideline, Treating Tobacco Use and Dependence, based on the literature review and expert panel opinion, are as follows: 1. Tobacco dependence is a chronic condition that often requires repeated intervention. However, effective treatments exist that can produce long-term or even permanent abstinence. 2. Because effective tobacco dependence treatments are available, every patient who uses tobacco should be offered at least one of these treatments: Patients willing to try to quit tobacco use should be provided with treatments identified as effective in this guideline. Patients unwilling to try to quit tobacco use should be provided with a brief intervention designed to increase their motivation to quit. 3. It is essential that clinicians and health care delivery systems (including administrators, insurers, and purchasers) institutionalize the consistent identification, documentation, and treatment of every tobacco user seen in a health care setting. 4. Brief tobacco dependence treatment is effective, and every patient who uses tobacco should be offered at least brief treatment. 5. There is a strong dose-response relation between the intensity of tobacco dependence counseling and its effectiveness. Treatments involving person-to-person contact (via individual, group, or proactive telephone counseling) are consistently effective, and their effectiveness increases with treatment intensity (eg, minutes of contact). 6. Three types of counseling and behavioral therapies were found to be especially effective and should be used with all patients attempting tobacco cessation: Provision of practical counseling (problem-solving/skills training); Provision of social support as part of treatment (intra-treatment social support); and Help in securing social support outside of treatment (extra-treatment social support). 7. Numerous effective pharmacotherapies for smoking cessation now exist. Except in the presence of contraindications, these should be used with all patients attempting to quit smoking. Five first-line pharmacotherapies were identified that reliably increase long-term smoking abstinence rates: -Bupropion SR -Nicotine gum -Nicotine inhaler -Nicotine nasal spray -Nicotine patch. Two second-line pharmacotherapies were identified as efficacious and may be considered by clinicians if first-line pharmacotherapies are not effective: -Clonidine -Nortriptyline. Over-the-counter nicotine patches are effective relative to placebo, and their use should be encouraged. 8. Tobacco dependence treatments are both clinically effective and cost-effective relative to other medical and disease prevention interventions. As such, insurers and purchasers should ensure that: All insurance plans include as a reimbursed benefit the counseling and pharmacotherapeutic treatments identified as effective in this guideline, and Clinicians are reimbursed for providing tobacco dependence treatment just as they are reimbursed for treating other chronic conditions. The updated guideline is divided into eight chapters that provide an overview including methods (Chapter 1), information on the assessment of tobacco use (Chapter 2), brief clinical interventions, both for patients willing and unwilling to make a quit attempt at this time (Chapter 3), intensive clinical interventions (Chapter 4), systems interventions for health care administrators, insurers, and purchasers (Chapter 5), the scientific evidence supporting the guideline recommendations (Chapter 6), and special populations and topics (Chapters 7 and 8). A comparison of the findings of the updated guideline with the original guideline reveals the considerable progress made in tobacco research over the brief period separating these two publications. Tobacco dependence is now increasingly recognized as a chronic disease, one that typically requires ongoing assessment and repeated intervention. In addition, the updated guideline offers the clinician many more efficacious treatment strategies than were identified in the original guideline. There are now seven different efficacious agents in the smoking cessation pharmacopoeia, allowing the clinician and patient many different medication options. In addition, recent evidence has identified new, efficacious counseling strategies. In particular, proactive telephone counseling is efficacious, as is counseling that helps smokers attain social support outside of the treatment context. The updated guideline also reveals greater evidence of the strong dose-response relation between counseling intensity and the likelihood of long-term abstinence from tobacco. Indeed, the data are compelling that pharmacologic and counseling treatment each independently boost cessation success; these data suggest that optimal cessation outcomes may require the combined use of both counseling and pharmacotherapy. Finally, there is increasing evidence that the success of any tobacco dependence treatment strategy or effort cannot be divorced from the health care system in which it is embedded. Data strongly indicate that effective tobacco interventions require coordinated interventions. Just as the clinician must intervene with his or her patient, so must the health care administrator, insurer, and purchaser foster and support tobacco intervention as an integral element of health care delivery. Health care administrators and insurers should ensure that clinicians have the training and support, and receive the reimbursement necessary to achieve consistent, effective intervention with tobacco users. One important conclusion of this guideline is that the most effective way to move clinicians to intervene is to provide them with information regarding multiple efficacious treatment options and to ensure that they have ample institutional support to use these options. Indeed, in this guideline, the panel encourages a culture of health care in which failure to treat tobacco use - the chief cause of preventable disease and death - constitutes an inappropriate standard of care.

Author-supplied keywords

  • *tobacco dependence/dm [Disease Management]
  • *tobacco dependence/dt [Drug Therapy]
  • *tobacco dependence/ep [Epidemiology]
  • *tobacco dependence/th [Therapy]
  • United States
  • algorithm
  • amfebutamone/ae [Adverse Drug Reaction]
  • amfebutamone/ct [Clinical Trial]
  • amfebutamone/do [Drug Dose]
  • amfebutamone/dt [Drug Therapy]
  • amfebutamone/pe [Pharmacoeconomics]
  • article
  • bupropion sr
  • clinical trial
  • clonidine/ad [Drug Administration]
  • clonidine/ae [Adverse Drug Reaction]
  • clonidine/ct [Clinical Trial]
  • clonidine/do [Drug Dose]
  • clonidine/dt [Drug Therapy]
  • clonidine/pe [Pharmacoeconomics]
  • clonidine/po [Oral Drug Administration]
  • clonidine/td [Transdermal Drug Administration]
  • cost effectiveness analysis
  • counseling
  • drug absorption
  • drug approval
  • drug cost
  • drug efficacy
  • drug induced disease/si [Side Effect]
  • health care cost
  • health care management
  • health insurance
  • health service
  • human
  • meta analysis
  • nicotine gum
  • nicotine/ad [Drug Administration]
  • nicotine/ae [Adverse Drug Reaction]
  • nicotine/cb [Drug Combination]
  • nicotine/ct [Clinical Trial]
  • nicotine/do [Drug Dose]
  • nicotine/dt [Drug Therapy]
  • nicotine/ih [Inhalational Drug Administration]
  • nicotine/it [Drug Interaction]
  • nicotine/na [Intranasal Drug Administration]
  • nicotine/pe [Pharmacoeconomics]
  • nicotine/pk [Pharmacokinetics]
  • nicotine/po [Oral Drug Administration]
  • nicotine/pr [Pharmaceutics]
  • nicotine/td [Transdermal Drug Administration]
  • nicotrol inhaler
  • nortriptyline/ae [Adverse Drug Reaction]
  • nortriptyline/ct [Clinical Trial]
  • nortriptyline/do [Drug Dose]
  • nortriptyline/dt [Drug Therapy]
  • nortriptyline/pe [Pharmacoeconomics]
  • practice guideline
  • public health
  • reward
  • screening
  • smoking cessation
  • social support
  • training
  • unclassified drug

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Fiore M.C.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free